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ABSTRACT
Targeting immune checkpoint molecules has become a major new strategy in 
the treatment of several cancers. Indoleamine 2,3-dioxygenase (IDO)-inhibitors are 
a potential next-generation immunotherapy, currently investigated in multiple phase 
I-III trials. IDO is an intracellular immunosuppressive enzyme and its expression/
activity has been associated with worse prognosis in several cancers. 
The aim of this study was to investigate the expression pattern of IDO in 
colorectal cancer (CRC). In a cohort of 94 CRC patients, primary tumors (PTs) with 
corresponding tumor-draining lymph nodes (TDLNs, n = 93) and extranodal/distant 
metastases (n = 27) were retrospectively analyzed by immunohistochemical staining 
for IDO, CD8 and Foxp3. 45 MSS and 37 MSI-H tumors were selected to compare IDO 
expression, as these tumors are considered to have different immunogenicity.
A highly consistent expression pattern of IDO was observed in the PT, TDLNs and 
metastases, indicating that immune resistance may be determined very early in the 
disease course. IDO was expressed both by tumoral cells and host endothelial cells and 
these expressions were highly correlated (p < 0.001). IDO expression was observed 
more frequently in the MSI-H subset compared with the MSS subset (43% vs 22% 
for tumoral expression (p = 0.042) and 38% vs 16% for endothelial expression (p = 
0.021)). Endothelial IDO expression was demonstrated to be a negative prognostic 
marker for recurrence free survival independent of disease stage and DNA mismatch 
repair (MMR) status (HR 20.67, 95% CI: 3.05–139.94; p = 0.002). These findings 
indicate that endothelial IDO expression in primary CRC, in addition to the MMR 
profile, may be helpful in disease stratification. 
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INTRODUCTION
Colorectal cancer (CRC) is one of the leading 
causes of cancer-related deaths worldwide [1]. Current 
treatment regimens rely on combinations of surgery and 
chemotherapy, radiation therapy and/or targeted therapy 
(anti-EGFR and anti-angiogenic therapies), depending 
on TNM staging (American Join Committee on Cancer, 
AJCC) [2]. 5-year survival rates vary from 85–100% in 
local disease (stage I & II) to 30–40% in regional disease 
(stage III) to less than 5% in systemic disease (stage IV) [3].
Insights in the complex immune regulation at the 
level of the tumor microenvironment with subsequent 
development of immune checkpoint inhibitors have 
revolutionized treatment of several cancers. Durable 
responses and improved survival rates with programmed 
cell death-1 (PD-1)-inhibitors have been observed in 
malignant melanoma, non-small-cell lung cancer (NSCLC), 
renal cell carcinoma and bladder cancer [4–6], changing 
the therapeutic field in these cancer types significantly. 
Numerous clinical trials are currently investigating these 
agents in other cancers, including CRC. Despite these 
encouraging results, the objective response rate (ORR) in 
patients under immunotherapy remains incomplete and 
durable responses are attained in a limited subgroup.
Indoleamine 2, 3-dioxygenase (IDO) may be a new 
target amenable to inhibition in the treatment of several 
cancers. IDO is an immunosuppressive intracellular 
enzyme that initiates the catabolism of the essential 
amino acid tryptophan to kynurenine and its downstream 
metabolites. IDO has been demonstrated to be an 
endogenous mechanism of acquired peripheral immune 
tolerance in vivo, which can act as a mechanism facilitating 
immune escape in cancer [7]. Expression of IDO has been 
associated with worse prognosis in several tumor types, 
amongst which melanoma. A highly consistent expression 
pattern of IDO was observed in the primary tumor, the 
sentinel lymph node and metastatic tissues of melanoma 
patients, indicating that immune suppression is determined 
very early in the disease course of these patients [8].
IDO may be a general principle of acquired immune 
tolerance, implicating that IDO checkpoint inhibition 
might prove beneficial in various cancer types. Several 
phase I/II clinical trials with different IDO-inhibitors are 
under way [7]. Epacadostat (INCB024360, Incyte) and 
indoximod (NLG-8189, NewLinkGenetics), two orally 
available IDO-inhibitors, have both been demonstrated 
in a phase I study to be well tolerated in patients with 
advanced malignancies [9, 10]. In colorectal cancer, four 
phase I/II studies with epacadostat combined with PD-1 
inhibitors are currently recruiting patients.
Several independent studies revealed a negative 
prognostic value of IDO in CRC. IDO expression in 
the PT has been reported to correlate with development 
of lymph node metastases and shorter overall survival 
[11]. A negative impact on survival was also observed 
with IDO expression in tumor draining lymph nodes 
(TDLNs) [12]. Moreover, strong IDO expression at the 
primary seemed to be associated with development 
of metachronous metastases [13–15]. Paradoxically, 
tumoral IDO expression was recently reported to be a 
positive prognostic marker on disease-free survival in 
microsatellite instable (MSI-H) CRCs [16].
The aims of this study were to investigate (1) the 
consistency of IDO expression in the PT, TDLN and 
metastatic tissue, (2) a correlation of IDO expression 
with tumor-infiltrating lymphocytes (TILs) at the PT, 
(3) differences of IDO expression according to the DNA 
mismatch repair (MMR) profile, (4) the prognostic 
influence of IDO on recurrence free survival (RFS).
RESULTS
IDO expression is highly consistent across 
disease stage 
In the PT, two major patterns of IDO expression 
were identified. A paranuclear dot-like IDO staining 
could be observed in neoplastic cells (Figure 1A). High 
IDO expression in tumor cells (2+ or 3+) was detectable 
in 30.9% (29/94) of cases. IDO could also be observed 
in endothelial cells in the peri-tumoral stroma in 25.5% 
(24/94) of patients (Figure 1B). Complete concordance 
of tumoral and endothelial IDO expression was seen in 
84.0% (79/94) of patients, illustrating an association 
between these 2 distinct expression patterns in the PT 
(p < 0.001). Tumoral IDO expression did not significantly 
vary across disease stage at diagnosis: stage I: 27.3% 
(3/11), stage II: 27.6% (8/29), stage III: 31.4% (11/35) 
and stage IV: 36.8% (7/19) (p = 0.901). Neither did IDO 
expression by endothelial cells: stage I: 45.5% (5/11), 
stage II: 13.8% (4/29), stage III: 28.6% (10/35) and stage 
IV: 26.3% (5/19) (p = 0.204). In the TDLNs, a similar 
tumoral and endothelial IDO expression pattern was 
observed. There was a strong association between tumoral 
and endothelial IDO staining in the TDLNs (p ≤ 0.001). 
Endothelial IDO positivity was present in 25.6% (11/43) 
of the TDLNs that were tumor-free. In 10 patients for 
whom both tumor-uninvaded and invaded TDLNs were 
available, a significant association in endothelial IDO 
expression was seen (p = 0.022). 
For analysis of IDO consistency, TDLNs of 93 cases 
and distant metastases of 27 cases were available. Both 
endothelial and tumoral IDO expression in the PT were 
consistently expressed in the TDLNs (resp. p < 0.001 and p < 
0.001) and metastatic tissue (resp. p = 0.009 and p < 0.001). 
IDO expression and the local immune infiltrate
CD8+ cells were more frequently present in MSI-H 
tumors (p = 0.010). ROC analysis was performed to 
dichotomize CD8+ cells in a ‘low’ and ‘high’ subset (cut-
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off value 87.96 cells/mm2). Using this cut-off value, a 
highly significant prognostic role for CD8 on RFS was 
observed (Figure 2, log-rank test, p = 0.004, cohort 2).
No significant differences in tumoral CD8+ cells 
could be observed in tumors with ‘high’ versus ‘low’ 
tumoral IDO expression in the PT (p = 0.963) nor in 
tumors with present versus absent endothelial IDO 
expression (p = 0.577). 
No associations of Foxp3 with MMR status, CD8 
cell count or tumoral/endothelial IDO expression were 
observed.
IDO expression is correlated with MSI status
Microsatellite instability was highly correlated with 
proximal tumor location (p < 0.001).
Moderate or strong tumoral IDO expression was present 
in 43.2% (16/37) of MSI-H tumors compared to 22.2% (10/45) 
of MSS tumors (p = 0.042). Endothelial IDO expression in 
MSI-H tumors was also significantly higher compared to MSS 
(37.8% (14/37) versus 15.6% (7/45), p = 0.021). 
Prognostic impact of IDO expression 
The prognostic relevance of IDO expression for RFS 
was evaluated in stage I-III patients of cohort 2. Tumoral 
IDO expression did not affect RFS (p = 0.548, log-rank 
test). Patients with endothelial IDO expression had shorter 
RFS time compared to patients without endothelial IDO 
expression (mean RFS: 41 months (95% CI: 26.19–55.64) 
compared to mean RFS: 61 months (95%CI: 51.71–70.88); 
p = 0.143, log-rank test).
Figure 1: Representative scoring system of tumoral and peritumoral endothelial IDO immunohistochemistry in the 
primary tumor. (A) no expression (0), weak expression (1+), moderate expression (2+) and strong expression (3+). For further analysis, 
tumoral IDO expression was dichotomized into an IDO-low expressing group (0 and 1+) and an IDO-high expressing group (2+ and 3+). 
(B) absence (left) and presence (right) of IDO expression by endothelial cells in the primary tumor.
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Multivariate analysis with a Cox proportional hazard 
regression model including TNM stage, endothelial IDO 
expression and MMR status demonstrated that endothelial 
IDO expression (HR: 20.67, 95% CI: 3.05–139.94; p = 
0.002) and MSS status (HR: 24.62, 95% CI: 2.38–254.36; 
p = 0.007) both negatively affect RFS, independent of 
each other and of disease stage (Table 1, upper panel). 
Moreover, endothelial IDO expression predicted relapse 
independent of the CD8 count (Table 1, lower panel).
In order to estimate the combined prognostic 
impact of endothelial IDO expression and MMR status, 
patients were subdivided in 4 groups: IDO negative 
MSS/IDO positive MSS/ IDO negative MSI-H or IDO 
positive MSI-H. Univariate log-rank survival analysis 
demonstrated divergent RFS curves for the 4 subgroups 
subgroups (Figure 3: stage I-III patients, p = 0.010). IDO 
negative MSI-H showed the most favourable prognosis 
(3.5 year RFS of 100%), whereas IDO positive MSS 
had the worst outcome with a median RFS of 4 months 
(95% CI: 0.00–8.29).
DISCUSSION
Study of the tumor microenvironment is emerging 
as an essential parameter in the understanding of the 
interaction between the tumor and the hosts’ immune 
system. Since many years the number of TILs has been 
associated with improved survival and a favourable 
disease course in various cancers. Galon et al. established 
the “immunoscore”, which is based on the enumeration 
of CD3+ and CD8+ TILs and was proven to be a strong 
and independent prognostic tool in CRC [17]. An initial 
anti-tumoral immune response may be skewed/deviated 
towards immune tolerance and several mechanisms for 
this have been reported [18]. It is becoming clear that IDO 
may play a central role in this, by the induction of anergy 
in cytotoxic T lymphocytes and stimulation of regulatory 
T cells [7, 19].
The aim of this research was to study IDO 
expression in CRC and its relation to disease stage, 
MMR status and disease relapse. We report a highly 
consistent IDO expression in the PT, the corresponding 
TDLN and metastatic tissue of CRC patients, similar to 
findings in melanoma [8]. Tumoral IDO expression was 
highly correlated with peri-tumoral expression by host 
endothelial cells. Of note, this endothelial IDO expression 
was not limited to tumor-invaded TDLNs, but was also 
detected in uninvaded TDLNs. The highly consistent 
expression pattern of IDO, together with the observation 
that IDO is present in tumor-uninvaded TDLNs, indicates 
that a climate of immune tolerance may be determined 
very early in disease. 
In melanoma, peri-tumoral IDO expression had 
a significant impact on the immune cells at the level of 
the PT and TDLN [8]. In CRC, no significant correlation 
between IDO expression and CD8+ cells was observed. 
In a previous study by our group including 265 CRC 
patients no association was found either [14]. However, 
Figure 2: Kaplan–Meier curves of recurrence free survival (RFS) according to frequency of CD8+cells in stage I–III 
patients.
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normal numbers of CD8 positive cells do not provide 
information on their functionality. Experiments in rats 
have demonstrated that CD8+ cells in an IDO-high in vivo 
tissue environment were not eliminated and were still 
viable, but lost their cytotoxic function [20]. 
Immunotherapy has dramatically changed the 
therapeutic landscape in several solid tumors. In CRC, 
PD-1 and CTLA-4 pathways have been the most studied to 
date. The potential benefit of PD-1 inhibitors in metastatic 
patients with a deficient MMR profile was first reported 
in a phase I trial with nivolumab [21]. Only one patient, 
who was demonstrated to have a MSI-H tumor, achieved 
a durable complete response. Improved response rates in 
MSI-H metastatic tumors were confirmed in a phase II trial 
with pembrolizumab, with ORR and 20-week-PFS rates of 
resp. 40% and 78% for MSI-H tumors and resp. 0% and 
11% for MSS tumors [22]. These promising results lead 
to accelerated FDA approval of anti-PD-1 therapy to treat 
MMR deficient cancer patients who progress on standard 
therapy.
The potential of PD-L1 as a biomarker for response 
to PD-1 inhibitors is currently unclear and seems to differ 
between tumor types. A phase II study demonstrated that 
responses on nivolumab in CRC patients were independent 
of the observed PD-L1 expression in MSI-H tumors [23]. 
These results indicate that PD-L1 is not able to reliably 
predict clinical benefit of PD-1 blockade in MSI-H CRC 
patients. Recent phase I studies have been completed with 
an IDO-inhibitor, epacadostat (INCB024360, Incyte), 
demonstrating reasonable tolerability and successful 
inhibition of IDO activity in colorectal carcinoma and 
melanoma (NCT01195311). Combinatorial data is not yet 
available for colorectal cancer patients, however encouraging 
efficacy results of epacadostat with pembrolizumab were 
obtained in patients with other advanced cancer types 
(melanoma, renal cell cancer and NSCLC; Keynote 037/
NCT02178722). At present it is unknown whether IDO 
expression can be used as a biomarker for response to IDO 
inhibition [7].
We report higher IDO expression in tumors with 
MSI-H compared to MSS. A previous study by Llosa 
et al. demonstrated higher expression of IDO+ TILs in 
MSI-H tumors. This result was based on RT-qPCR in 
TILs [24]. Our results support previous findings by Zhang 
et al., demonstrating elevated tumoral IDO expression in 
MSI-H CRCs [25]. More important, we report an even 
more pronounced difference in IDO expression by host 
endothelial cells in the peritumoral stroma. To the best 
of our knowledge, higher endothelial IDO expression in 
MSI-H CRCs has not been reported in literature before. 
How endothelial IDO expression is induced exactly is 
currently not fully understood. The increased number of 
tumor-specific neoantigens in MSI-H tumors, which are 
induced by frameshift mutations, could be one possible 
explanation. Next generation sequencing studies have 
reported that MSI-H tumors harbor 10 to 50 times more 
Figure 3: Kaplan–Meier curves of recurrence free survival (RFS) according to endothelial IDO expression and MMR 
profile in stage I-III patients.
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mutations than MSS tumors [26]. It is hypothesized 
that the active immune tumor microenvironment, which 
is stimulated by this increased neoantigen load, is 
counterbalanced by the upregulation of IDO, as a negative 
feedback mechanism with subsequent evasion of these 
tumors from the immune system. However our data show 
that IDO expression is not limited to MSI-H CRC alone 
but can also occur in MSS CRC.
IDO has been reported as an independent prognostic 
marker in several cancers, including CRC [11–14]. In 
this study, our data indicate that IDO expression by host 
endothelial cells is a negative prognostic factor for RFS, 
independent of disease stage and MMR profile (HR 20.67, 
95% CI: 3.05–139.94). Combined presence of endothelial 
IDO expression and MSS status was associated with the 
worst prognosis with a median RFS of 4 months. 
From a clinical perspective, it is essential to 
better identify individual patients that will benefit from 
immunotherapy, in order to reach the best treatment 
efficacy in individual patients taking into account that 
these treatments are associated with significant costs and 
potential toxicities. A recent study in a small group of 
patients with metastatic renal cell carcinoma demonstrated 
that endothelial IDO expression was more frequently 
present in the group of responders to anti-PD1 therapy 
versus non-responders (100% versus 33.3%) [27]. Our 
data suggest that IDO-inhibitory strategies might be 
beneficial in both MSI-H and MSS tumors. These results 
are supported by a previous study by Angelova et al., 
demonstrating a strong immunological response was 
counterbalanced by increased gene expression of several 
immunoinhibitory molecules (CTLA-4, PD-1 and IDO) in 
both MSI and hypermutated MSS CRCs [28].
Taken together, we demonstrate an early and 
consistent expression pattern of IDO across different 
disease stages in CRC patients. The detection of such 
early signal of immune resistance in cancer could be 
important as a biomarker for prognosis and (immuno-) 
therapy response. Although endothelial IDO expression is 
more frequent in tumors with microsatellite instability, it 
is associated with decreased RFS, independent of MMR 
status. These findings indicate that endothelial IDO 
expression, in addition to MMR status, may be helpful in 
the stratification of CRC patients in future clinical trials. 
MATERIALS AND METHODS
Patients
A total of 94 patients who underwent surgical 
resection of primary colon (n = 89) and rectal (n = 5) 
carcinoma and for whom TDLN and metastatic tissue 
were available were enrolled in this retrospective study. 
Staging at time of diagnosis was performed according to 
the AJCC TNM classification (7th edition). Patients who 
received pre-operative chemotherapy or radiotherapy were 
Table 1: Multivariate Cox regression model for recurrence free survival
95% Confidence Interval for HR
Recurrence free survival Coefficient HR Lower Upper P-value 
Clinical stage at diagnosis
Stage IV (reference) - - - 0.037
Stage I −19,063 0.000 - - 0.973
Stage II −3,360 0.035 0.002 0.512 0.014
Stage III −4,254 0.014 0.001 0.251 0.004
Endothelial IDO expression
Absent (reference) - - - -
Present −3.029 20,670 3,053 1,39,943 0.002
MMR status
MSI-H (reference) - - - -
MSS 3,204 24,626 2,384 2,54,358 0.007
Endothelial IDO expression
Absent (reference) - - - -
Present −1.578 0.206 0.054 0.789 0.021
CD8+cells/mm2
Low (reference) - - - -
High 1,930 6,891 1,422 33,399 0.017
Abbreviations: HR, hazard ratio; IDO, indoleamine 2,3-dioxygenase; MMR status, DNA mismatch repair status; MSI-H, 
microsatellite unstable; MSS, microsatellite stable.
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excluded from the cohort. Basic patient demographic data 
are summarized in Table 2. This study was approved by 
the local ethical committee.
Formalin-fixed, paraffin embedded (FFPE) primary 
tumor (PT) tissues of 94 patients were retrieved from 
the pathology department of the Erasme University 
Hospital (n = 39) and the Ghent University Hospital 
(n = 55). Corresponding tumor draining lymph nodes 
(TDLNs, n = 93) and metastatic tissues (lung or liver, 
n = 27) were retrieved. Both uninvaded and invaded 
TDLNs were studied (resp. n = 43 and n = 40). In 10 
cases, both were available. Only resections were used 
for immunohistochemical staining. In order to study 
differences in IDO expression between MSS and MSI-H 
CRC and the prognostic significance of IDO expression, 
only the Ghent University Hospital cohort was used. 
MMR status was determined by immunohistochemistry 
for mismatch repair proteins MLH1, MSH2, MSH6 and 
PMS2. Normal MMR profile (MSS, n = 45) was defined as 
nuclear expression of all four markers in neoplastic cells and 
tumors were regarded as MSI-H (n = 37) when at least one 
marker was negative in the presence of a positive internal 
control.
Immunohistochemistry
Immunohistochemical staining of 4 μm sections was 
conducted according to standard avidin-biotin-peroxidase 
protocols using monoclonal antibodies against IDO 
(clone 10.1, 1/200, Millipore, Billerica, USA), Foxp3 
(clone PCH101, 1/50, eBioscience, San Diego, USA) 
and CD8 (clone CD8/144B, RTU, Dako). For antigen 
retrieval, slides were boiled (97° C) for 20 min (PT Link, 
Dako). A mouse linker (Dako) was added to the protocol 
in order to amplify the signal of the primary mouse anti-
IDO and anti-Foxp3. Antibody detection was visualized 
using 3-amino-9-ethylcarbazole (AEC) for IDO and 
diaminobenzidene (DAB) for Foxp3 and CD8 detection. 
Sections were counterstained with hematoxylin.
Evaluation of immunohistochemistry
IDO
IDO expression was analyzed in neoplastic cells 
(I) and in endothelial cells in the peri-tumoral stroma 
(II). (I) In tumoral cells, the intensity of IDO staining 
Table 2: Patient and tumor characteristics
  Total number of cases Cohort 1 Cohort 2
Number of patients, n 94 39 55
Age at diagnosis (median -IQR) 65 years (55–76) 64 years (54–72) 66 (58–77)
Gender 
Male 55 (58) 24 (62) 31 (56)
Female 39 (41) 15 (38) 24 (44)
Clinical stage at diagnosis
Stage I 11 (12) 2 (5) 9 (16)
Stage II 29 (31) 5 (13) 24 (44)
Stage III 35 (37) 16 (41) 19 (35)
Stage IV 19 (20) 16 (41) 3 (6)
Post-operative chemotherapy 
(No-Folfox-5-FU-Folfiri)
Stage I 11-0-0-0 (100-0-0-0) 2-0-0-0 (100-0-0-0) 9-0-0-0 (100-0-0-0)
Stage II 19-3-5-2 (66-10-17-7) 3-0-2-0 (60-0-40-0) 16-3-3-2 (67-13-13-8)
Stage III 12-19-2-2 (34-54-6-6) 4-10-2-0 (25-63-13-0) 8-9-0-2 (42-47-0-11)
Stage IV 4-11-0-4 (21-58-0-21) 3-10-0-3 (19-63-0-19) 1-1-0-1 (33-33-0-33)
Tumor location
right-sided 51 (54) 18 (46) 33 (60)
left-sided 43 (46) 21 (54) 22 (40)
MMR statusa
MSS 45 (55) 17 (63) 28 (51)
 MSI-H 37 (45) 10 (37) 27 (49)
Data given are numbers, percentages are given between brackets (%)
aThe MMR profile could not be determined for 12 cases, due to lack of residual tumor material.
Abbreviations: IQR, interquartile range; MMR status, DNA mismatch repair status; MSI-H, microsatellite unstable; MSS, 
microsatellite stable.
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was scored semiquantitatively using a four-tiered grading 
system: no expression (0), weak expression (1+), moderate 
expression (2+) or strong expression (3+) [14]. For further 
analysis, tumoral IDO expression was dichotomized into 
an IDO-low expressing group (0 and 1+) versus an IDO-
high expressing group (2+ and 3+). (II) Endothelial IDO 
expression in the peri-tumoral stroma was scored as 
“present” or “absent” as earlier described [8].
The scoring procedure was carried out by two 
independent observers (AM and LV), who were blinded to 
the patient clinical data. Cohen’s kappa value for tumoral 
IDO expression (4-tiered scale) and endothelial IDO 
expression were respectively κ = 0.864 and κ = 0.852, 
which can both interpreted as a ‘near-perfect agreement’ 
according to Landis and Koch [29]. 
FoxP3 and CD8
Stained whole slide tissue sections were digitized 
and used for automated quantification of Foxp3+ or CD8+ 
cells. Regions of interest (ROI) were delineated manually 
per slide. A user-customized algorithm was constructed 
in Definiens Tissue studio (Definiens Architect XD 64 
2.6). Thresholds for cell segmentation, nucleus detection 
and immunohistochemistry marker intensity were set 
manually. The fraction of positive cells was calculated as 
the number of high intensity DAB positive stained cells 
divided by the total number of cells in the respective 
tumor areas (=ROIs). 
Statistical analysis
For continuous variables, mean values between 
2 groups were compared by the Mann–Whitney U-test. 
The Fisher’s exact test was used for the comparison of 
categorical variables. Cohen’s kappa value was calculated 
to evaluate interobserver agreement for IDO scoring. 
Recurrence free survival (RFS) was estimated by the 
Kaplan–Meier method and compared by the log-rank test. 
RFS was defined as date of diagnosis to date of recurrence 
or date of death of disease, in case no recurrence was 
reported previously. Multivariate survival analysis was 
performed utilizing the Cox proportional hazard model. 
All statistical analyses were performed using SPSS 24.0 
(SPSS Inc, Chicago, IL, USA), a p-value (two-sided) less 
than 0.05 was considered statistically significant.
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